Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
In selected patients with acute pulmonary embolism(PE), low dose (50mg/2h) recombinant tissue
plasminogen activator (rt-PA) regimen had been reported to have less bleeding tendency than
the FDA-approved rt-PA 100mg/2h regimen 100mg/2h regimen (3% vs.10%), it is worthwhile to
reveal whether low dose rt-PA plus low molecular weight heparin (LMWH) can rapidly reverses
RV pressure overload in PE, but not increase bleeding and other adverse events. The aim of
the study is to compare thrombolytic treatment with LMWH in patients with acute normotensive
PE with right ventricular dysfunction(RVD).
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Chao Yang Hospital
Collaborator:
Ministry of Science and Technology of the People´s Republic of China